Evidence map›Paper›PMID 29421932›Full record

ReviewExpert opinion on therapeutic targets2018

The 70-kDa heat shock protein (Hsp70) as a therapeutic target for stroke.

Jong Youl Kim, Yeonseung Han, Jong Eun Lee, Midori A Yenari

Open access · greenAbstract readReview
In one paragraph

Review in Expert opinion on therapeutic targets, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Jong Youl Kima Department of Anatomy , Yonsei University College of Medicine , Seoul , Republic of Korea.
Yeonseung Hana Department of Anatomy , Yonsei University College of Medicine , Seoul , Republic of Korea.
Jong Eun Leea Department of Anatomy , Yonsei University College of Medicine , Seoul , Republic of Korea.
Midori A Yenaric Department of Neurology , University of California, San Francisco & the San Francisco Veterans Affairs Medical Center , San Francisco , CA , USA.
Yonsei University · KRUniversity of California, San Francisco · US

Funding

Inflammatory Mechanisms in Cerebral IschemiaR01NS040516 · NINDS · STANFORD UNIVERSITY · PI YENARI, MIDORI A · 2001 to 2014
$4.6M
Calcium release-activated calcium (CRAC) channel inhibitors in experimental strokeR03NS101246 · NINDS · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI YENARI, MIDORI A · 2017 to 2018
$153k
Heat shock proteins in brain ischemia and strokeI01BX000589 · VA · VETERANS AFFAIRS MED CTR SAN FRANCISCO · PI YENARI, MIDORI A · 2011 to 2019
–
BLRD VA I01 BX000589NINDS NIH HHS R01 NS040516NINDS NIH HHS R03 NS101246
6 · The paper itself

Abstract

introductionThe 70-kDa heat shock protein (Hsp70) is a cytosolic chaperone which facilitates protein folding, degradation, complex assembly, and translocation. Following stroke, these functions have the potential to lead to cytoprotection, and this has been demonstrated using genetic mutant models, direct gene transfer or the induction of Hsp70 via heat stress, approaches which limit its translational utility. Recently, the investigation of Hsp70-inducing pharmacological compounds, which, through their ability to inhibit Hsp90, has obvious clinical implications in terms of potential therapies to mitigate cell death and inflammation, and lead to neuroprotection from brain injury. Areas covered: In this review, we will focus on the role of Hsp70 in cell death and inflammation, and the current literature surrounding the pharmacological induction in acute ischemic stroke models with comments on potential applications at the clinical level. Expert opinion: Such neuroprotectants could be used to synergistically improve neurological outcome or to extend the time window of existing interventions, thus increasing the numbers of stroke victims eligible for treatment.

Indexed as

AnimalsBrain IschemiaCell DeathDrug DesignHSP70 Heat-Shock ProteinsHSP90 Heat-Shock ProteinsHumansMolecular Targeted TherapyNeuroprotective AgentsProtein FoldingStrokeHSP70 Heat-Shock ProteinsHSP90 Heat-Shock ProteinsNeuroprotective Agents70-kDa heat shock protein (Hsp70)apoptosischaperoninflammationischemic strokeneuroprotection

Identifiers

PMID29421932
PMCPMC6059371
OpenAlexW2790125860

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.